Impax Asset Management Group
NBIX icon

Impax Asset Management Group’s Neurocrine Biosciences NBIX Stock Holding History

Impax Asset Management Group’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27M Buy
160,000
+85,000
+113% +$12.6M 0.18% 91
2026
Q1 		$9.88M Hold
75,000
– – 0.07% 157
2025
Q4 		$10.6M Hold
75,000
– – 0.07% 146
2025
Q3 		$10.5M Sell
75,000
-40,000
-35% -$5.42M 0.06% 140
2025
Q2 		$14.5M Buy
115,000
+15,000
+15% +$1.72M 0.08% 119
2025
Q1 		$11.1M Sell
100,000
-161,599
-62% -$20.5M 0.07% 136
2024
Q4 		$35.7M Buy
261,599
+176,599
+208% +$21.8M 0.16% 96
2024
Q3 		$9.79M Buy
85,000
+35,000
+70% +$4.8M 0.04% 166
2024
Q2 		$6.88M Hold
50,000
– – 0.03% 196
2024
Q1 		$6.9M Sell
50,000
-60,000
-55% -$8.19M 0.03% 199
2023
Q4 		$14.5M Sell
110,000
-25,000
-19% -$2.88M 0.06% 140
2023
Q3 		$15.2M Sell
135,000
-65,000
-33% -$6.84M 0.07% 131
2023
Q2 		$18.9M Hold
200,000
– – 0.08% 126
2023
Q1 		$20.2M Buy
200,000
+25,000
+14% +$2.6M 0.08% 125
2022
Q4 		$20.9M Buy
175,000
+25,000
+17% +$2.93M 0.09% 122
2022
Q3 		$15.9M Buy
+150,000
New +$15.2M 0.08% 128
2020
Q2 		– Sell
-75,000
Closed -$6.49M – 289
2020
Q1 		$6.49M Buy
+75,000
New +$7.34M 0.09% 130
2019
Q4 		– Sell
-22,000
Closed -$1.98M – 295
2019
Q3 		$1.98M Buy
+22,000
New +$2.06M 0.03% 190

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Impax Asset Management Group's NBIX Position: Q2 2026 in Review

Impax Asset Management Group increased its Neurocrine Biosciences (NBIX) stake by 113% in Q2 2026, buying an estimated $12.6M and bringing the position to 160,000 shares worth $27M. The position accounts for 0.18% of the portfolio, ranked #91.

Impax Asset Management Group first reported a position in NBIX in Q3 2019 and has held it in 18 quarters since. The position peaked at $35.7M in Q4 2024. 771 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Impax Asset Management Group held 160,000 shares of Neurocrine Biosciences worth $27M as of Q2 2026.
  • Impax Asset Management Group bought 85,000 Neurocrine Biosciences shares in Q2 2026, an estimated $12.6M.
  • Neurocrine Biosciences made up 0.18% of Impax Asset Management Group's portfolio in Q2 2026, its #91 holding.
  • Impax Asset Management Group first reported a position in Neurocrine Biosciences in Q3 2019 and has held it in 18 quarters since.
  • Impax Asset Management Group's Neurocrine Biosciences position peaked at $35.7M in Q4 2024.
  • 771 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Impax Asset Management Group's 13F filing for Q2 2026, filed 11 Aug 2026.